LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Search

Omnicell Inc

Cerrado

SectorSanidad

36.29 0.3

Resumen

Variación precio

24h

Actual

Mínimo

36.29

Máximo

36.79

Métricas clave

By Trading Economics

Ingresos

-7.5M

-2M

Ventas

3.4M

314M

P/B

Media del Sector

912.5

121.746

BPA

0.51

Margen de beneficios

-0.645

Empleados

3,600

EBITDA

-10M

21M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+59.45% upside

Dividendos

By Dow Jones

Próximas Ganancias

5 may 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-560M

1.7B

Apertura anterior

35.99

Cierre anterior

36.29

Noticias sobre sentimiento de mercado

By Acuity

40%

60%

87 / 351 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Omnicell Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

15 feb 2026, 23:21 UTC

Adquisiciones, fusiones, absorciones

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15 feb 2026, 23:45 UTC

Charlas de Mercado

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15 feb 2026, 23:40 UTC

Charlas de Mercado

Gold Falls on Possible Position Adjustments -- Market Talk

15 feb 2026, 23:06 UTC

Ganancias

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15 feb 2026, 23:04 UTC

Ganancias

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15 feb 2026, 23:04 UTC

Ganancias

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15 feb 2026, 23:01 UTC

Ganancias

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15 feb 2026, 23:01 UTC

Ganancias

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15 feb 2026, 22:53 UTC

Adquisiciones, fusiones, absorciones

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15 feb 2026, 22:53 UTC

Adquisiciones, fusiones, absorciones

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15 feb 2026, 22:52 UTC

Adquisiciones, fusiones, absorciones

Qube Shareholders to Receive A$5.20/Share in Cash

15 feb 2026, 22:52 UTC

Adquisiciones, fusiones, absorciones

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15 feb 2026, 22:22 UTC

Adquisiciones, fusiones, absorciones

BlueScope CEO Tania Archibald Speaking on a Call With Media

15 feb 2026, 22:17 UTC

Adquisiciones, fusiones, absorciones

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

15 feb 2026, 22:16 UTC

Adquisiciones, fusiones, absorciones

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

15 feb 2026, 22:14 UTC

Adquisiciones, fusiones, absorciones

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

15 feb 2026, 22:14 UTC

Adquisiciones, fusiones, absorciones

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

15 feb 2026, 20:48 UTC

Ganancias

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

15 feb 2026, 20:47 UTC

Ganancias

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

15 feb 2026, 20:46 UTC

Ganancias

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

15 feb 2026, 20:45 UTC

Ganancias

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

15 feb 2026, 20:44 UTC

Ganancias

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

15 feb 2026, 20:44 UTC

Ganancias

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

15 feb 2026, 20:43 UTC

Ganancias

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

15 feb 2026, 20:42 UTC

Ganancias

BlueScope Net Debt A$2.2 Million at Dec. 31

15 feb 2026, 20:42 UTC

Ganancias

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

15 feb 2026, 20:41 UTC

Ganancias

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

15 feb 2026, 20:40 UTC

Ganancias

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

15 feb 2026, 20:40 UTC

Ganancias

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

15 feb 2026, 20:39 UTC

Ganancias

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Comparación entre iguales

Cambio de precio

Omnicell Inc previsión

Precio Objetivo

By TipRanks

59.45% repunte

Estimación a 12 Meses

Media 58.2 USD  59.45%

Máximo 70 USD

Mínimo 49 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Omnicell Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

6

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

24.23 / 30.44Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

87 / 351 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Omnicell Inc

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
help-icon Live chat